期刊
BIOORGANIC CHEMISTRY
卷 110, 期 -, 页码 -出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bioorg.2021.104782
关键词
Synthesis; Structure-activity relationship; Relaxin family peptide receptor 4; Selective agonist; Molecular docking
资金
- National Natural Science Foundation of China [81872915, 82073904, 21302202, 81973373, 81773792]
- National Science & Technology Major Project Key New Drug Creation and Manufacturing Program of China [2018ZX09735-001, 2018ZX09711002-002-005, 2018ZX09711002-002-011]
- National Key R&D Program of China [2018YFA0507000]
- Novo NordiskCAS Research Fund [NNCAS-2017-1-CC]
Relaxin family peptide receptors RXFPs are potential therapeutic targets for neurological, cardiovascular, and metabolic diseases, with RXFP3 and RXFP4 identified as promising targets for treatment. A new selective RXFP4 agonist was discovered through high-throughput screening, with structural modifications leading to a compound with improved selectivity and efficacy for RXFP4 compared to the original scaffold.
Relaxin family peptide receptors (RXFPs) are the potential therapeutic targets for neurological, cardiovascular, and metabolic indications. Among them, RXFP3 and RXFP4 (formerly known as GPR100 or GPCR142) are homologous class A G protein-coupled receptors with short N-terminal domain. Ligands of RXFP3 or RXFP4 are only limited to endogenous peptides and their analogues, and no natural product or synthetic agonists have been reported to date except for a scaffold of indole-containing derivatives as dual agonists of RXFP3 and RXFP4. In this study, a new scaffold of tricyclic derivatives represented by compound 7a was disclosed as a selective RXFP4 agonist after a high-throughput screening campaign against a diverse library of 52,000 synthetic and natural compounds. Two rounds of structural modification around this scaffold were performed focusing on three parts: 2-chlorophenyl group, 4-hydroxylphenyl group and its skeleton including cyclohexane-1,3-dione and 1,2,4-triazole group. Compound 14b with a new skeleton of 7,9-dihydro-4H-thiopyrano[3,4-d][1,2,4]triazolo[1,5-a] pyrimidin-8(5H)-one was thus obtained. The enantiomers of 7a and 14b were also resolved with their 9-(S)conformer favoring RXFP4 agonism. Compared with 7a, compound 9-(S)-14b exhibited 2.3-fold higher efficacy and better selectivity for RXFP4 (selective ratio of RXFP4 vs. RXFP3 for 9-(S)-14b and 7a were 26.9 and 13.9, respectively).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据